Cargando…
Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20(+) B-cell lymphoma: a multicenter, randomized, double-blind, parallel-controlled study
This multicenter, randomized, double-blind, parallel-controlled trial aimed to compare the pharmacokinetics (PK) of IBI301 with rituximab in patients with CD20-positive (CD20(+)) B-cell lymphoma, who achieved a complete response/unconfirmed complete response after standard treatments. Patients were...
Autores principales: | Jiang, Bo, Ke, Xiaoyan, Zhang, Qingyuan, Xu, Wei, Su, Hang, Huang, Jie, Zhang, Mingzhi, Wang, Huaqing, Jin, Chuan, Zhu, Jun, Liu, Li, Cai, Zhen, Zhao, Xielan, Zhou, Jianfeng, Zhang, Xiaohong, Liu, Jing, Zhou, Hui, Yu, Jie, Sun, Xing, Qi, Junyuan, Qiu, Lugui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7363910/ https://www.ncbi.nlm.nih.gov/pubmed/32669656 http://dx.doi.org/10.1038/s41598-020-68360-0 |
Ejemplares similares
-
Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma
por: Shi, Yuankai, et al.
Publicado: (2021) -
Ibis
por: Vargas Vila, José María, 1860-1933
Publicado: (1908) -
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
por: Shi, Yuankai, et al.
Publicado: (2020) -
IBI: Identification of Biomarker Genes in Individual Tumor Samples
por: Li, Jie, et al.
Publicado: (2019) -
The Genomic Footprints of the Fall and Recovery of the Crested Ibis
por: Feng, Shaohong, et al.
Publicado: (2019)